Table 1.
Comparison between groups: Lepidic Adenocarcinoma and Non-Predominant-Lepidic Adenocarcinoma.
| Variables | Total (n = 388) | Lepidic Adenocarcinoma (n = 161) | Non-Predominant-Lepidic Adenocarcinoma (n = 227) | p-Value |
|---|---|---|---|---|
| Age (years) | 66.7 ± 7.25 | 65.9 ± 8.09 | 67.6 ± 6.27 | 0.19 |
| History of cancer, n (%) | 108 (27%) | 46 (29%) | 62 (27%) | 0.78 |
| Tumor size (cm) | 1.96 ± 1.01 | 1.91 ± 0.95 | 1.99 ± 1.05 | 0.32 |
| Pure GGO, n (%) | 162 (42%) | 108 (67%) | 54 (24%) | <0.0001 |
| N0, n (%) | 353 (91%) | 151 (94%) | 202 (89%) | 0.10 |
| N1, n (%) | 26 (7%) | 8 (5%) | 18 (8%) | 0.25 |
| N2, n (%) | 9 (2%) | 2 (1%) | 7 (3%) | 0.23 |
| Right Upper Lobe, n (%) | 123 (32%) | 48 (30%) | 75 (33%) | 0.45 |
| Right Middle Lobe, n (%) | 18 (5%) | 10 (6%) | 8 (4%) | 0.79 |
| Right Lower Lobe, n (%) | 71 (18%) | 29 (18%) | 42 (18%) | 0.9 |
| Left Upper Lobe, n (%) | 117 (30%) | 46 (29%) | 71 (31%) | 0.56 |
| Left Lower Lobe, n (%) | 59 (15%) | 28 (17%) | 31 (14%) | 0.19 |
| Segmentectomy, n (%) | 90 (23%) | 38 (24%) | 52 (23%) | 0.17 |
| Lobectomy, n (%) | 255 (66%) | 111 (69%) | 144 (63%) | 0.26 |
| Wedge resection, n (%) | 43 (11%) | 12 (7%) | 31 (14%) | 0.06 |
| Adjuvant Chemotherapy, n (%) | 66 (17%) | 24 (15%) | 42 (18%) | 0.86 |
| Radiotherapy, n (%) | 16 (4%) | 6 (4%) | 10 (5%) | 0.74 |
| Recurrence, n (%) | 58 (15%) | 14 (8%) | 44 (19%) | 0.003 |
| Disease Free Survival (months) | 49.2 ± 37.3 | 64.9 ± 39.4 | 37.7 ± 31 | <0.001 |
| Overall Survival (months) | 52.2 ± 36.8 | 66.4 ± 38.9 | 41 ± 31.4 | <0.001 |